Background A genome-wide association study identifi ed 13 single-nucleotide polymorphisms (SNPs) signifi cantly associated with Parkinson's disease. Small-scale replication studies were largely non-confi rmatory, but a meta-analysis that included data from the original study could not exclude all SNP associations, leaving relevance of several markers uncertain.
Introduction
Genome-wide screening for genetic associations is a promising approach for identifi cation of the genetic determinants of common complex diseases. 1 One of the fi rst applications of this emerging approach has been in the genetics of Parkinson's disease. A high-resolution genome-wide analysis of 198 345 single-nucleotide polymorphisms (SNPs) identifi ed 13 SNPs exhibiting signifi cant association with Parkinson's disease in a twotiered study of white Americans with Parkinson's disease and healthy related and unrelated controls. 2 After the publication of that study, several investigators tried to replicate one or more of these associations. [3] [4] [5] [6] [7] The results of these follow-up studies have been largely nonconfi rmatory, leading to much controversy. 8, 9 In view of the importance of understanding the contribution of genetics to Parkinson's disease and the desire to provide further clarity to this research area, The Michael J Fox Foundation for Parkinson's Research, which funded the original genome-wide study, coordinated its own independent large-scale multicentre international replication eff ort. This study consisted of 14 international centres that contributed a combined sample size of more than 12 000 individuals. This is the largest genetics study of its kind to date for Parkinson's disease and the largest replication eff ort of genome-widederived associations in any specialty.
Methods

Study population
Investigators from three existing Edmond J Safra Global Genetics Consortia funded by The Michael J Fox Foundation for Parkinson's Research were invited to participate (table 1) . 10, 11 Investigators involved in the original genome-wide study 2 were not invited in order to maintain independence between the two studies.
Procedures
Genotyping of DNA samples was undertaken either on-site (seven teams at an investigator laboratory or core facility) or through commercial contract (seven teams at Genoscreen, Lille, France). Genotypes were ascertained for all 13 SNPs reported in the original genome-wide study 2 by use of several genotyping platforms following standard protocols: TaqMan SNP Genotyping Assays (Applied Biosystems, Foster City, CA, USA); LightCycler with HybProbes (Roche, Basel, Switzerland); MassARRAY Analyzer Compact (Sequenom, San Diego, CA, USA); and Pyrosequencing on a PSQ HS 96(A) system (Biotage AB, Uppsala, Sweden). A random selection of at least 5% of samples was regenotyped to determine precision; genotyping error rates were lower than 0·5% for all genotyping sites.
Statistical analysis
In the analyses, participants were stratifi ed according to the team that recruited them and to their ethnic origin (white non-Hispanic, Hispanic, Asian, African American, Native American, and other). We used an exact test to assess among controls in each stratum whether the genotype distributions for each of the 13 SNPs violated Hardy Weinberg equilibrium (HWE). This test was done only among women for the X-linked SNP9 (rs7878232). Deviation from HWE was deemed signifi cant for p<0·05, but we accepted that given the extreme number of HWE tests done (n=403) some strata might exhibit signifi cant HWE deviation simply by chance. We used the same allele coding as in the original genome-wide study; 2 the reference allele was the major frequency allele for all SNPs except for SNP3 (rs2313982), SNP8 (rs2245218), and SNP10 (rs1509269).
For quantitative syntheses we fi rst did analyses adjusted for team and ethnic origin. Analyses were further adjusted for age at study entry and sex; for these analyses we excluded data from strata with fewer than 20 individuals. We assessed genetic eff ects with the assumption of log-additive (multiplicative) models in logistic regressions and we synthesised results across strata with both fi xed and random-eff ects models. Fixed-eff ects models assume that odds ratios (ORs) are constant across all teams and ethnic subgroups and that observed diff erences are due to chance. Random-eff ects models allow that results might be genuinely diff erent (heterogeneous) across teams and ethnic subgroups and they take into account between-study heterogeneity. In the presence of heterogeneity, randomeff ects syntheses are preferable. 12, 13 We tested for betweenstudy heterogeneity with the χ²-based Q statistic (formally deemed signifi cant for p<0·10) 13 and quantifi ed its extent with I², which ranges from 0% to 100% and represents the proportion of between-study variability ascribed to heterogeneity rather than to chance.
14 Values for I² of 0-24% suggest little heterogeneity, 25-49% refl ect moderate heterogeneity, 50-74% refl ect large heterogeneity, and more than 75% refl ect very large heterogeneity. We assessed whether any summary results were nominally signifi cant at p<0·05 and at p<0·004 (correcting for 13 polymorphisms).
Subgroup analyses were undertaken according to ethnic origin, age at study entry (cutoff at 25th percentile=60 years), sex, and presence or not of family history of Parkinson's disease in fi rst-degree relatives. We assessed whether any diff erences between subgroups were nominally signifi cant at p<0·05 and at p<0·0013 (correcting for 13 polymorphisms and three subgroup analyses per polymorphism).
Finally, we also did meta-analyses incorporating the data from tier two of the original genome-wide association study 2 as well as from preliminary replication eff orts published until May 20, 2006 . [3] [4] [5] [6] [7] We combined ORs and their variances (using consistent allele coding) with the ORs and variances from each team and subgroup included in our collaborative analysis using the inverse variance method. We used both fi xed and random-eff ects models. Heterogeneity was assessed with the Q and I² statistics, as described above. All analyses were done with Intercooled Stata 8.2 (College Station, TX, USA).
Role of the funding source
The Michael J Fox Foundation for Parkinson's Research played a part in the identifi cation of study investigators; coordination of the study design; data collection, analysis, and interpretation; and writing of the report. Other funding sources played no role outside of study sponsorship. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
The 14 teams contributed a total sample size of 5578 patients and 6765 controls. Of these, we excluded 46 participants because of missing information about sex, 19 because of missing information about ethnic origin, 52 twins from one study, and 18 male participants whose genotyping spuriously showed heterozygosity for SNP9 (located on the X chromosome), an indication of data error or Klinefelter syndrome. The remaining 5526 patients and 6682 controls were included in the analysis. Most (n=10767; 88%) were of white, nonHispanic descent, whereas 896 (7%) were of Asian descent, 344 (3%) were of Hispanic descent, 141 (1%) were of African-American descent, 21 (0·2%) were Native Americans or Pacifi c Islanders, and 39 (0·3%) were of other descent. The proportion of men ranged between 41% and 62% across participating teams and ethnic groups. The mean age at diagnosis of Parkinson's disease ranged between 55·4 years and 67·5 years and the mean age at study entry ranged between 64·2 years and 74·6 years for patients and between 60·9 years and 73·8 years for controls. Among participants with Parkinson's disease, 547 (13%) had a documented family history of the disease, whereas 3846 reported no such family history, and for 1133 this information was unknown (table 1) . The distribution of genotypes was ascertained for each SNP and for each team and ethnic subgroup (webtable 1). Genotype distributions were consistent with HWE among controls in most of the strata for the thirteen SNPs. Genotypes were not in HWE for seven SNPs (1, 2, 3, 5, 6, 8, 9 ) in a total number of 13 strata: p values were greater than 0·01 in ten strata and lower than 0·01 in three strata (SNP3 in the Payami study, white non-Hispanic, SNP9 in the Kawakami study, Asian or Pacifi c Islander, and in the Hadjigeorgiou study, white non-Hispanic).
Summary ORs for all 13 SNPs in random-eff ects models adjusted for team and ethnic origin were very close to unity, ranging from 0·92 to 1·07 (table 2) , indicating no signifi cant association, even at an uncorrected p value threshold of 0·05. The 95% CIs were also very tight, excluding ORs smaller than 0·84 or larger than 1·18. There was no heterogeneity for seven SNPs, little heterogeneity for fi ve SNPs, and moderate heterogeneity for SNP13 (p=0·07). The fi xed-eff ects calculation yielded similar-if not identical-results; nominal signifi cance was seen only for SNP5 (p=0·049). Analyses restricted to participants of white, non-Hispanic descent also showed very similar estimates, with summary ORs between 0·93 and 1·09 in both fi xed and random-eff ects calculations.
When adjustment for age at study entry and sex was taken into account, the results were the same (table 3) . In random-eff ects calculations, all summary ORs were between 0·89 and 1·09 and their 95% CIs excluded ORs smaller than 0·81 or larger than 1·19. There was no signifi cant heterogeneity for any SNP, and the largest I² was only 27%. Fixed-eff ects estimates were very similar. None of the SNPs had even nominal signifi cance. Additionally, no signifi cant associations were seen when analyses were restricted to white, non-Hispanic descent populations. Heterogeneity remained at low levels, except for SNP4 (p=0·02, I²=51%). Exclusion of the strata in which controls were not in HWE did not modify these fi ndings (data not shown).
Data were very limited for populations of non-white, non-Hispanic descent; however, the available results were consistent across ethnic subgroups (webtables 2-5). In analyses adjusted for team, p values for the comparison between populations of white, non-Hispanic descent and of Asian descent (the two most common groups) were less than 0·05, except for SNP11 (p=0·010). In analyses adjusted for age at study entry and sex, the corresponding p value was also signifi cant for SNP7 (p=0·04). For none of the SNPs did the p value fall below the threshold of 0·004 (critical 95% alpha threshold accounting for 13 SNPs). For analyses by age at study entry, diff erent cutoff s were used with similar results.
Nine of the 13 polymorphisms did not give any nominally signifi cant signals in any subgroup analyses with randomeff ects modeling (fi gure 1). For some SNPs, nominal signifi cance (p<0·05) was seen in specifi c subgroups: familial Parkinson's disease (OR 0·67, 95% CI 0·53-0·84; p=0·0007) and male population (0·90, 0·81-1·00; p=0·045) for SNP4; older (≥60 years) participants (1·09, 1·01-1·18; p=0·028) and familial Parkinson's disease (1·27, 1·06-1·53; p=0·009) for SNP8; non-familial Parkinson's disease (0·92, 0·84-1·00; p=0·049) and male population (0·88, 0·77-1·00; p=0·048) for SNP9; and familial Parkinson's disease (0·85, 0·74-0·99; p=0·030) for SNP13. Only the genetic eff ect of SNP4 in familial Parkinson's disease crossed the p value threshold after correction for 13 SNPs and four subgroup analyses (p<0·0013). However, given that random-eff ects models give more weight to smaller studies than to larger studies, this eff ect was probably mainly driven by strata with very small numbers. In most studies, the number of familial Parkinson's disease cases was small, whereas the Payami study contributed 44% of all familial Parkinson's disease cases. In the Payami study the OR in familial Parkinson's disease for SNP4 was 1·02 (95% CI 0·78-1·33). When compared against their complementary subgroups, only three of these seven eff ects were nominally diff erent at p<0·05: SNP4 in familial versus non-familial Parkinson's disease (p=0·008) and SNP8 in older versus younger age populations (p=0·010) and in familial versus non-familial Parkinson's disease (p=0·029). However, all of these three nominally signifi cant subgroup eff ects were in the opposite direction compared with the eff ects reported in the original whole-genome association study; 2 thus, they do not indicate replication.
In meta-analyses including our data as well as the tiertwo data from the original whole-genome association study 2 and several smaller replication studies, [3] [4] [5] [6] [7] none of the 13 SNPs showed nominally signifi cant association even at p>0·064; all summary ORs were between 0·95 and 1·08 with 95% CIs excluding ORs smaller than 0·87 or larger than 1·18. Heterogeneity was formally signifi cant only for SNP13 (p=0·03, I²=34%). Apart from SNP13, there was generally limited heterogeneity (I²<23%). Exclusion of the original tier-two data, which were also exploratory (almost 2000 SNPs were tested), did not aff ect our results. If anything, heterogeneity tended to diminish (SNP13 was only marginally signifi cantly heterogeneous, p=0·09, I²=26%). The 95% CIs of the tier-two data typically did not overlap at all with the overall metaanalysis (fi gure 2). N=number of teams and ethnic subgroups contributing to the analysis. FE=fi xed eff ects. RE=random eff ects. The reference allele was the major frequency allele for all SNPs, except for SNP3 (rs2313982), SNP8 (rs2245218), and SNP10 (rs1509269). *Nominal statistical signifi cance without correction for multiple comparisons (p<0·05 for summary ORs and p Het <0·10 for heterogeneity). N=number of teams and ethnic subgroups contributing to the analysis. FE=fi xed eff ects. RE=random eff ects. The reference allele was the major frequency allele for all SNPs, except for SNP3 (rs2313982), SNP8 (rs2245218), and SNP10 (rs1509269). *Nominal statistical signifi cance without correction for multiple comparisons (p<0·05 for summary ORs and p Het <0·10 for heterogeneity). 
Discussion
The present results do not lend support to the fi nding that the 13 SNPs reported in the original two-tier genomewide association study 2 are genetic susceptibility loci for Parkinson's disease. Although eff ects were seen in a few subgroup analyses, these did not correspond in direction to the original report, suggesting that they were probably spurious.
Our collaborative study is the largest replication genetics study undertaken in Parkinson's disease to date. Although the study included populations with large ethnic heterogeneity, the results were consistent, with no major statistical between-study heterogeneity in any of the main analyses. Genotypes in a few strata were not in HWE, but this is not surprising given the large number of tests done. In most of these cases deviations were not very signifi cant (p>0·01); exclusion from our analyses of the three strata where p values were below 0·01 did not change our fi ndings.
One interpretation of this lack of replication is that the 13 SNPs highlighted in the original genome-wide study 2 were not true risk factors but were probably false-positive fi ndings. Indeed, assuming that 1% (using p<0·01) of the SNPs assayed in the original report would be expected to show an association to Parkinson's disease by chance alone, most SNPs (1862 of 198 345; 0·9%) carried from tier one into tier two were probably false positives. Although slightly more SNPs (26 of 1793; 1·4%) than expected by chance showed signifi cant association with Parkinson's disease in tier two, only around half of them (11 of 26) showed the same direction of eff ect in both tiers; the other 15 SNPs were extreme opposites that could be seen simply by chance. 15 Furthermore, none of the SNPs identifi ed in either tier of the original report met statistical-albeit conservative-criteria after adjustment for multiple comparisons.
The study by Maraganore and colleagues 2 is the fi rst of its type for Parkinson's disease and was a valiant eff ort given that technology and bioinformatics are still relatively immature for doing whole-genome association studies. However, based on the current replication results, and in hindsight, it is perhaps useful to discuss several points that could inform future eff orts focused on the genetics of Parkinson's disease and other common diseases of multifactorial origin.
First, the eff ect sizes for genetic determinants of Parkinson's disease may be small; evidence from genedisease associations identifi ed to date suggests that, with some exceptions, most associations have ORs in the range of 1·1-1·6. 16 Because the power calculations of the original genome-wide study 2 were based on an OR of 2·0, the original study was underpowered to detect eff ect sizes in the lowest range. Tier one of the original genomewide study 2 used a sibship-based association design to identify initial SNP associations, and was powered to detect ORs of 2·0 or higher. Although this design has the advantage of being most robust to population stratifi cation, it can be underpowered relative to caseunrelated control studies. 17 With 332 matched caseunrelated control pairs, tier two was also underpowered to detect ORs in the very low range. Limited power may also result in false-negative fi ndings. Some genuine determinants of Parkinson's disease could therefore still be among those screened in the original study. Along these lines, we applaud Fung and colleagues 18 for making their genome-wide SNP analysis dataset publicly available. In parallel, The Michael J Fox Foundation for Parkinson's Research has been planning a mechanism by which to make the original dataset of Maraganore and colleagues, 2 as well as the current replication data, available to researchers within the near future. Further scrutiny of these rich databases and integration with future eff orts will be important.
Second, studies may require greater genome coverage and more informative markers to be able to detect true genetic determinants of Parkinson's disease. Coverage of the 250K SNP chip from Perlegen Sciences that was used by the original genome-wide study might be less than 60%, even when linkage disequilibrium of 80% is allowed. This might not have provided adequate coverage of the genome and informative markers could have been left out despite the relatively large number of SNPs. Even though current chips are often termed as whole-genome screens, in fact they off er only partial coverage of the estimated 10 million variants in the human genome. 19 This would be even more problematic if some genetic determinants are highly population-specifi c or if they express themselves through complex interactions between several markers or environmental factors. Our study only sought to replicate in a larger population the specifi c 13 SNPs highlighted in Maraganore and colleagues' study 2 as having signifi cant association with Parkinson's disease because we felt such a replication would be a critical fi rst step to understanding these results. Further study of the genetic regions surrounding these SNPs using greater marker density could still be useful.
Third, designing a whole-genome study that has adequate statistical power in the context of multiple hypothesis testing is challenging. Consensus is lacking for the most appropriate statistical methods to use. Some investigators favour an approach that uses an initial sample that is relatively small with the use of a liberal p value, followed by a second screen in an independent population that is of a larger size with a more stringent p value. 1 In the case of the original genome-wide study, 2 the second tier sample size was smaller (n=332 pairs) than the fi rst tier sample size (n=443 pairs). Other approaches for selection of samples for each stage of a whole-genome association study of Parkinson's disease have also been proposed. 8 The relative merits of various multistage approaches need to be validated empirically based on whether their application is successful. Interestingly, the most clear success from genome-wide approaches to date (the identifi cation of a genetic marker for age-related macular degeneration) 20 used an extremely small sample size. In this case, however, the eff ect size was unusually large. That being said, none of the other genetic determinants for complex diseases identifi ed through genome-wide approaches has been subjected to the extent of replication that we have done, so conclusions from these studies need to be drawn cautiously. [21] [22] [23] [24] Finally, the main eff ects of genetic factors can be masked in the presence of underlying gene-environment interaction. If environmental factors are necessary for interacting with genetic variants to increase the risk of Parkinson's disease, studies that do not measure and account for this interaction might fail to identify important susceptibility genes.
Whole-genome association studies are still in their infancy and it is perhaps not surprising that the fi rst attempt at a genome-wide association study of Parkinson's disease did not yield replicable results. Several recent advances could improve such studies in the future, including the identifi cation of tag SNPs to more comprehensively cover the genome or the selection of a dense map of missense SNPs in coding and regulatory regions. A drop in the per-marker cost of genotyping platforms might bring this technology into practical reach of more investigators. Future approaches might also include doing whole-genome scans in founder populations or in early onset Parkinson's disease populations in which the genetic contributions to Parkinson's disease risk are strongest. 25 In any case, future whole-genome association studies of Parkinson's disease will necessitate larger numbers of participants and careful attention to patient selection for each stage of study. Contributors AE, LN, HP, JI, and BF coordinated the study, contributed to study design, data analysis and interpretation, coordinated data collection, and assisted with writing of the manuscript. MD, JM, and RMM genotyped samples for multiple sites and provided additional overall technical assistance. TT assisted with overall data analysis and interpretation and manuscript preparation. All other authors assisted in coordinating sample preparation and data collection for each individual study site. All authors contributed to critical review of the manuscript and have seen and approved the fi nal version. 
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